podophyllotoxin has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiba, N; Itoh, G; Iwabuchi, Y; Kohyama, A; Kuriyama, S; Shibata, H; Tanaka, M; Yashiro, M | 1 |
| All-Ericsson, C; Aström, K; Axelson, M; Economou, MA; Girnita, A; Girnita, L; Larsson, O; Seregard, S | 1 |
2 other study(ies) available for podophyllotoxin and B16 Melanoma
| Article | Year |
|---|---|
Identification of anti-cancer chemical compounds using Xenopus embryos.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Benzofurans; Carbolines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Evaluation, Preclinical; Embryo Loss; Embryo, Nonmammalian; Female; Gastrulation; Glioma; Indole Alkaloids; Melanoma, Experimental; Mice; Microtubules; Neoplasm Invasiveness; Paclitaxel; Podophyllotoxin; Rats; Receptors, CXCR4; Xenograft Model Antitumor Assays; Xenopus | 2016 |
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Topics: Animals; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, SCID; Neoplasm Invasiveness; Phosphorylation; Podophyllotoxin; Receptor, IGF Type 1; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2006 |